LL-37
The only human cathelicidin antimicrobial peptide
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
Summary
The only antimicrobial peptide of the cathelicidin family produced by humans. It derives from a larger protein, hCAP-18, and takes part in the body's response to microbes, inflammation and wound repair. In the research peptide market it usually appears as a lyophilized vial.
Quick reference
- What it is
- The only human cathelicidin; a 37-amino-acid defense peptide.
- Trial route
- Topical wound gel, 0.5–1.6 mg/mL, 2×/week.
- Community route
- Subcutaneous injection from a reconstituted vial — with no human trial support.
- Status
- Not approved; investigational as ropocamptide.
Dosing guide
| Feature | Commonly reported |
|---|---|
| Starting range | 100-200 mcg/day |
| Upper range cited | Up to 500 mcg/day |
| Frequency | 1×/day, generally 5 days a week |
| Cycle length | 2-4 weeks, then a break |
| Route | Subcutaneous injection |
LL-37 Reconstitution Guide
| Dose | Volume | U-100 units |
|---|---|---|
| 100 mcg | 0.04 mL | 4 units |
| 200 mcg | 0.08 mL | 8 units |
| 250 mcg | 0.10 mL | 10 units |
| 500 mcg | 0.20 mL | 20 units |
LL-37 vs Nearby Peptides
| Peptide | Main research framing | Antimicrobial? |
|---|---|---|
| LL-37 | Host defense, wound healing, immune signaling | Yes |
| BPC-157 | Soft-tissue recovery interest | No |
| TB-500 | Recovery and tissue repair interest | No |
| KPV | Anti-inflammatory fragment interest | No |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.